Inventor · disambiguated record
Helen Hoerzer
Also filed as: HOERZER Helen
35 granted patents·4 pending applications·114 citations·filing 2016–2025
97Inventor score
Files withIMMATICS BIOTECHNOLOGIES GMBH39
Top patents by PatentIndex Score
39 records- 0198US11401310B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 2, 2022·2 cites·20 claims
- 0298US10934333B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Mar 2, 2021·4 cites·20 claims
- 0397US11485765B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Nov 1, 2022·4 cites·22 claims
- 0497US10738094B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Aug 11, 2020·6 cites·11 claims
- 0597US10485859B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Nov 26, 2019·6 cites·20 claims
- 0695US10000539B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Jun 19, 2018·10 cites·20 claims
- 0794US10533041B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 14, 2020·6 cites·22 claims
- 0894US10494413B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Dec 3, 2019·6 cites·20 claims
- 0994US10239925B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Mar 26, 2019·6 cites·20 claims
- 1094US10227388B2Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Mar 12, 2019·7 cites·17 claims
- 1194US10174089B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 8, 2019·6 cites·19 claims
- 1294US9908922B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Mar 6, 2018·7 cites·7 claims
- 1393US11912749B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 27, 2024·1 cites·20 claims
- 1493US11384129B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 12, 2022·1 cites·20 claims
- 1593US11384128B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 12, 2022·1 cites·20 claims
- 1693US11384127B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 12, 2022·1 cites·20 claims
- 1793US10472401B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Nov 12, 2019·6 cites·13 claims
- 1893US10464978B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Nov 5, 2019·6 cites·14 claims
- 1993US10280205B2Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptideIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted May 7, 2019·6 cites·20 claims
- 2093US10253076B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Apr 9, 2019·6 cites·17 claims
- 2193US10047131B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Aug 14, 2018·6 cites·12 claims
- 2292US11912748B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 27, 2024·1 cites·20 claims
- 2390US10596243B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Mar 24, 2020·1 cites·21 claims
- 2490US10213499B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 26, 2019·3 cites·12 claims
- 2590US10064929B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Sep 4, 2018·3 cites·13 claims
- 2688US11230581B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 25, 2022·1 cites·18 claims
- 2788US10376569B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 13, 2019·1 cites·21 claims
- 2886US2023227517A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2986US2023101093A1Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3083US12071458B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 27, 2024·0 cites·20 claims
- 3181US12226466B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 18, 2025·0 cites·17 claims
- 3279US2025144192A1Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2025·Application pending·0 cites
- 3377US10166278B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 1, 2019·0 cites·12 claims
- 3476US11065314B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 20, 2021·0 cites·18 claims
- 3576US10675338B1Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 9, 2020·0 cites·20 claims
- 3674US10143733B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Dec 4, 2018·0 cites·12 claims
- 3773US10238728B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Mar 26, 2019·0 cites·13 claims
- 3872US10143732B2Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Dec 4, 2018·0 cites·12 claims
- 3970US2018066032A1Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Helen Hoerzer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →